Temsirolimus News and Research

RSS
Temsirolimus is approved by the Food and Drug Administration (FDA) to treat advanced renal cell carcinoma (kidney cancer). Temsirolimus is also being studied in the treatment of other types of cancer. Temsirolimus is an ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.
Combination of molecularly targeted cancer drug and anti-malarial drug stops tumor growth

Combination of molecularly targeted cancer drug and anti-malarial drug stops tumor growth

Astellas, AVEO enter development, commercialization agreement for tivozanib

Astellas, AVEO enter development, commercialization agreement for tivozanib

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

Researchers discover several key mutations in pancreatic neuroendocrine tumors

Researchers discover several key mutations in pancreatic neuroendocrine tumors

Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in metastatic breast cancer

Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in metastatic breast cancer

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium

AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

Afinitor tablets decrease size of SEGA associated with tuberous sclerosis

Afinitor tablets decrease size of SEGA associated with tuberous sclerosis

Sexual issues a major concern for cancer patients taking new targeted drugs

Sexual issues a major concern for cancer patients taking new targeted drugs

AVEO presents tivozanib Phase 2 study results at ESMO Congress

AVEO presents tivozanib Phase 2 study results at ESMO Congress

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium

AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Kidney Cancer Canada applauds Ontario for granting coverage for RCC therapy TORISEL

Kidney Cancer Canada applauds Ontario for granting coverage for RCC therapy TORISEL

Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia

Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia